Some Conotoxin Patents via DELPHION [previously, IBM Patent Server]
AND US Patent and Trade Mark Office

See also:


WO0043409 Alpha-Conotoxin Peptides [The invention relates to relatively short peptides (termed alpha-conotoxins herein), about 10-25 residues in length which are naturally available in minute amounts in the venom of the cone snails or analagous to naturally available peptides, and which preferably include two disulfide bonds. The conotoxins, described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants]. IPO PCT Publications: July 27, 2000: Olivera, Layer, Watkins, Hillyard, McIntosh, Jones
NOTE: DNA sequences are provided for the following species of Conus: C. achatinus, C. aurisiacus, C. circumcisus, C. consors, C. monachus, C. erminius, C. geographus, C. magus, C. obscurus, C. purpurascens, C. radiatus, C. striatus, C. stercusmuscarum, C. sulcatus, C. textile. C. terebra, C. tulipa, C. vexillum and C. wittigi,
WO02079236 Alpha conotoxin peptides with analgesic properties [This invention relates to novel alpha-conotoxin-like peptides comprising the following sequence of amino acids: Xaa1CCSXaa2Xaa3Xaa4CXaa5Xaa6Xaa7Xaa8Xaa9Xaa10Xaa11C-NH2 in which Xaa1 is G or D; Xaa3 is proline, hydroxyproline or glutamine; each of Xaa2 to Xaa8 and Xaa11 is independently any amino acid; Xaa9 is proline, hydroxyproline or glutamine; Xaa10 is aspartate, glutamate or gamma -carboxyglutamate; Xaa11 is optionally absent; and the C-terminus is optionally amidated, with the proviso that the peptide is not alpha-conotoxin Ep1 or alpha-conotoxin Im1. The peptides are useful in the treatment or prevention of pain, in recovery from nerve injury, and in the treatment of painful neurological conditions such as stroke. WIPO PCT Publications: October 10, 2002: Bruce Livett, Zeinab Khalil, Kenwyn Gayler, John Down, David Sandall and David Keays]
6489298 US and Delphion Contulakin-G, analogs thereof and uses thereof [Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr.sub.10 -contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders. Date: Filed June 29, 2000. Issued December 3, 2002: Grey; Griffen; Olivera; Watkins; Hillyard; Imperial; Cruz; Wagstaff; Layer; Jones; and McCabe. ]
6307014 US and Delphion Conopeptides [Abstract: Substantially pure conopeptides containing .gamma.-carboxyglutamic acid are disclosed Date: October 23, 2001: Furie, Stenflo, Rigby and Roepstorff]
6284731 US and Delphion Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function [Abstract: Novel compounds and compositions for modulating NMDA receptor function comprising Conantokin-G and derivatives thereof; methods for modulating NMDA receptor function and methods for treating neuropsychopharmacological disorders, using the novel compounds and compositions of the invention; and a method for screening compounds capable of binding to a novel allosteric modulatory site, are described Date: September 4, 2001: Inventor: Maria-Luisa Maccecchini]
6277825 US and Delphion Use of conantokins for treating pain [Abstract: The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more .gamma.-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as pain, e.g., as an analgesic agent. Date: August 21, 2001: Inventors: Olivera, McIntosh, McCabe, Layer and Zhou]
6268473 US and Delphion .alpha.-conotoxin peptides [Abstract: The invention relates to relatively short peptides (termed .alpha.-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The .alpha.-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants. Date: July 31, 2001: Olivera, Layer, Watkins, Hillyard, McIntosh, Schoenfeld and Jones]
6265541 US and Delphion Uses of .alpha.-conotoxin peptides [Abstract: The present invention relates to the use of .alpha.-conotoxin peptides having the general formula Xaa1 -Xaa2 -Cys-Cys-Xaa3 -Xaa4 -Pro-Xaa5 -Cys-Xaa6 -Cys (SEQ ID NO: 1) for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1 is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2 is any amino acid, Xaa3 is any amino acid, Xaa4 is any amino acid, Xaa5 is any amino acid and Xaa6 represents a peptide of 3-7 amino acids. Disulfide linkages exist between the first and third cysteines and the second and fourth cysteines. Pro may be replaced with hydroxy-Pro. The C-terminus may contain a hydroxyl or an amide group, preferably an amide group. Date: July 24, 2001/ Dec. 23, 1998: Olivera, McIntosh, Yoshikami, Cartier and Luo]
WO09954350A1 Novel Omega Conotoxin Peptides [An isolated, synthetic or recombinant omega-conotoxin peptide in which the fourth loop between cysteine residues 5 and 6 comprises SEQ ID NO: 1 or such a sequence which has undergone one or more amino acid substitutions or side chain modifications, and uses therefor. SEQ ID NO: 1 comprises the amino acid sequence SGTVGR. The invention relates to novel peptides of the omega conotoxin class and their use as pharmacological tools in any indication where blockage of N-type calcium channels may be of benefit, for example in the reduction of neuronal damage following ischemia, production of analgesia, or enhancement of opiate analgesia, in the treatment of schizophrenia, stimulant induced psychoses, hypertension, inflammation and diseases which cause bronchoconstriction and in the inbibition of progression of neuropathic pain. WIPO PCT Publications: October 28, 1999: Drinkwater, Lewis, Alewood and Nielsen]
WO02060923A1 beta-Superfamily conotoxins [The present invention is directed to B-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to the nucleic acid sequences encoding the beta-superfamily conotoxin peptides and encoding beta-superfamily conotoxin propeptides, as well as the beta-superfamily conotoxin propeptides. IPO PCT Publications: August 8, 1998: Jones, Olivera, Watkins, Garrett
NOTE: DNA sequences are provided for the following species of Conus: C. achatinus, C.aurisiacus, C. baileyi, C. bocki, C. betulinus, C. capitaneus, C. chaldeus, C. cinereus, C. circumcisus, C. consors, C. coronatus, C. ebreus, C. emaciatus, C. flavidus, C. generalis, C. geographus, C. gladiator, C. litoglyphus, C. litteratus, C. loroisii, C. magus, C. miles, C. mureculatus, C. musicus, C. mustelinus, C. nobilis, C. parius, C. planorbis, C. pulicarius, C. purpurascens, C. rattus, C. stercusmuscaurum, C. striatus, C. striolatus, C. sulcatus, C. terebra, C. tulipa, C. vexillum and C. wittigi,
WO09824462A1 Use of alpha-conotoxin MII to treat disorders resulting from nicotine-stimulated dopamine release. [Use of alpha CTX MII for pharmacological manipulation of nicotinic receptors which have implications for a wide variety of disorders including psychotic, mood, movement and cognitive. WIPO PCT Publications]
WO09921878A1 Interaction of alpha-conotoxin peptides with neuronal nicotinic acetylcholine receptors. [to enable the design of .agr.-4/7 conotoxin peptide analogs and peptide mimetics which demonstrate the same specificity to neuronal nAChR. Such analogs and peptidemimetics are useful as cardiovascular agents and for treating or detectingsmall-cell lung carcinoma (SCLC). WIPO PCT Publications. May 6, 1999: Shon, Olivera, Rivier, Koerber, Shen, McIntosh, Cartier and Yoshikami]
6265541 (WO09933482A1) Uses of alpha-conotoxin peptides. [treating disorders regulated at neuronal nicotinic acetylcholine receptors. . WIPO PCT Publications]
WO09822126A1 Use of conotoxin peptides ImI and MII a cardiovascular agents. [Use of ImI and MII as heart rate regulating agents, blood pressure regulating agents and anti-arrhythmia agents. WIPO PCT Publications]
5969096 Conotoxin peptides. [CTXs that specifically target particular skeletal nAChRs, and NOT neuronal nAChRs]
5965534 Use of .omega.-conotoxin analogs for treating retinal and optic nerve head damage. [Use of w-CTX for prevention / treatment of retinal or optic nerve head damage in humans]
5929034 Use of .alpha.-conotoxin MII to treat disorders resulting from nicotine-stimulated dopamine release. [Method of treating a person with a mood disorder]
5922679 Use of .alpha.-conotoxin MII to treat disorders resulting from nicotine-stimulated dopamine release. [Method of treating a person with psychosis]
5866682 Conopeptides AuIA, AuIB and AuIC [ an alpha conotoxin that selectively targets alpha3beta4 subunit combination of neuronal-type nicotinic receptor]
5824645 Method of treating inflammation
5795864 Stable omega conopeptide formulations
5780433 Use of alpha-conotoxin MII to treat disorders resulting from nicotine stimulated dopamine release.
5739276 Conotoxin peptides [delta-conotoxin PVIA is vertebrate-specific and targets voltage-sensitive Na channels]
5719264 Conotoxin peptides [delta-conotoxin GmVIA activates sodium channels and u-O-Conotoxin peptides which block Na channels]
5700778 Conotoxins I [a-conotoxins - the DNA encoding such conotoxins having pesticidal properties can be incorporated as plant defense genes into plant species of interest]
5670622 Conotoxin peptide PIIIA [u-conotoxin from C. purpurascens]
5672682 Conotoxin peptide PVIIA [kappa-conotoxin from C. purpurascens]
5633347 Conotoxin peptides [A-lineage conotoxin peptides including a-,a-like & k-conotoxin peptides]
5595972 Conotoxin peptides [A-lineage conotoxin peptides:  to diagnose/treat small-cell carcinomas]
5432155 Conotoxins I [a-conotoxins which act at the neuromuscular junction inhibit synaptic transmission by targeting receptors such as the acetylcholine receptor and ion channels. The DNA encoding such conotoxins having pesticidal properties can be incorporated as plant defense genes into plant species of interest]
5424218 Screening method for neuroprotective compounds [makes use of w-contoxin MVIIA]
5403484 Viruses expressing chimeric binding proteins
5514774 Conotoxin peptides [A-lineage conotoxin peptides including a-,a-like & k-conotoxin peptides]
5589340 Process and primers for identifying nucleic acids encoding A-lineage conotoxin peptides [A-lineage conotoxin peptides including a-,a-like & k-conotoxin peptides]
5591821 Omega-conotoxin peptides
5587454 Omega conopeptide compositions
5571698 Directed evolution of novel binding proteins
5559095 Delayed treatment method of reducing ischemia-related neuronal damage
5677288 Use of aminoglycosides to protect against excitotoxic neuron damage
5625033 Totally synthetic affinity reagents
5562907 Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
5498538 Totally synthetic affinity reagents
5474547 Implanting devices for the focal release of neuroinhibitory compounds
5429921 Assays for agonists and antagonists of recombinant human calcium channels
5405749 Method for identifying and purifying a cancer associated retinopathy autoantigen, and testing patient serum for the autoantibody to the autoantigen
5386025 Calcium channel compositions and methods
5264371 Screening method for neuroprotective compounds [partially purified omega-conotoxin, reduces neuronal damage related to ischemic condition such as stroke]
5231011 Segregated folding determinants for small disufide-rich peptides. [Abstract: The preparation of small peptides with multiple disulfide bonds is accomplished by forming a prepropeptide with an N-terminal excised region separated from the cysteine-rich peptide by one or more cleavable amino acid residues. The excised region preferably consists of an N-terminal end providing a hydrophobic signal sequence domain having up to approximately 25 amino acids, and an intermediate central propeptide domain having a variable length of between about 5-50 amino acids. The N-terminal excised region serves as a folding template to direct the formation of specific disulfide bonds in the cysteine-rich peptide. The cysteine-rich peptide is cleaved by enzymes releasing the biologically active peptide. July 27, 1993: Hillyard and Olivera]
WO09313128A1 Methods for producing analgesia and enhancing opiate analgesia. [Abstract: Methods of producing analgesia and enhancing opiate analgesia are disclosed. The methods include administering a TVIA (SNX-185) or MVIIA (SNX-111) omega-conopeptide, or derivative thereof which is characterized by its ability to (a) inhibit voltage-gated calcium channels selectively in neuronal tissue as evidenced by the peptides' ability to inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed is a novel omega conotoxin peptide effective in producing analgesia. WIPO PCT Publications. July 8, 1993: Justice, Singh, Gohil, Valentino and Miljanich]
5189020 Method of reducing neuronal damage using omega conotoxin peptides [A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient. February 23, 1993: Miljanich, Bitner, Bowersox, Fox, Valentino and Yamashiro, Tsubokawa]
4447356 Conotoxins [The present invention provides bioactive peptides of generic formula [Figure] These peptides are extremely potent inhibitors of synaptic transmission at the neuromuscular junction, while at the same time lacing demonstrable inhibition of either nerve or muscle action potential propagation. The peptides are termed conotoxins herein. Naturally occurring conotoxins include conotoxin GI, GIA and GII. In conotoxin GI, U is Glu, V4 is Asn, V5 is Pro, V6 is Ala, W is Gly, X is Arg, Y is His, Z is Tyr, V12 is Ser and R is --NH2. Conotoxin GIA is identical to GI except R is --Gly--Lys--NH2. Conotoxin GII is identical to GI except that V4 is His, Z is Phe, and X is Lys. Conotoxin MI is identical to GI except that U is Gly-Arg, X is Lys and Y is Asn. May 8, 1984/June 4, 1982: Olivera, Cruz, Gray and Rivier]

Do you have any positive comments or/and questions ? Please send to Dr. Bruce Livett


Copyright 1998 Dynamix@WORK! All rights reserved. Last updated on August 10, 2005.